Page 1223 - Williams Hematology ( PDFDrive )

1198 Part IX: Lymphocytes and Plasma Cells

29. Cabral-Marques O, Klaver S, Schimke LF, et al: First report of the Hyper-IgM syndrome 60. Reith W, Mach B: The bare lymphocyte syndrome and the regulation of MHC expres-
Registry of the Latin American Society for Immunodeficiencies: Novel mutations, sion. Annu Rev Immunol 19:331–373, 2001.
unique infections, and outcomes. J Clin Immunol 34:146–156, 2014. 61. Sutor G, Fabel H: Sarcoidosis and common variable immunodeficiency. A case of a
30. Engel P, Eck MJ, Terhorst C: The SAP and SLAM families in immune responses and malignant course of sarcoidosis in conjunction with severe impairment of the cellular
X-linked lymphoproliferative disease. Nat Rev Immunol 3:813–821, 2003. and humoral immune system. Respiration 67:204–208, 2000.
31. Gilmour KC, Gaspar HB: Pathogenesis and diagnosis of X-linked lymphoproliferative 62. Vitiello L, Masci AM, Montella L, et al: Thymoma-associated immunodeficiency: A
disease. Expert Rev Mol Diagn 3:549–561, 2003. syndrome characterized by severe alterations in NK, T and B-cells and progressive
32. Marsh RA, Bleesing JJ, Chandrakasan S, et al: Reduced-intensity conditioning hemato- increase in naive CD8+ T Cells. Int J Immunopathol Pharmacol 23:307–316, 2010.
poietic cell transplantation is an effective treatment for patients with SLAM-associated 63. Trakatellis A, Dimitriadou A, Trakatelli M: Pyridoxine deficiency: New approaches in
protein deficiency/X-linked lymphoproliferative disease type 1. Biol Blood Marrow immunosuppression and chemotherapy. Postgrad Med J 73:617–622, 1997.
Transplant 20:1641–1645, 2014. 64. Small TN, Wall DA, Kurtzberg J, et al: Association of reticular dysgenesis (thymic alym-
33. Elder ME: T-cell immunodeficiencies. Pediatr Clin North Am 47:1253–1274, 2000. phoplasia and congenital aleukocytosis) with bilateral sensorineural deafness. J Pediatr
34. Edgar JD: T cell immunodeficiency. J Clin Pathol 61:988–993, 2008. 135:387–389, 1999.
35. Notarangelo LD, Roifman CM, Giliani S: Cartilage-hair hypoplasia: Molecular basis 65. Poliani PL, Facchetti F, Ravanini M, et al: Early defects in human T-cell development
and heterogeneity of the immunological phenotype. Curr Opin Allergy Clin Immunol severely affect distribution and maturation of thymic stromal cells: Possible implica-
8:534–539, 2008. tions for the pathophysiology of Omenn syndrome. Blood 114:105–108, 2009.
36. Maida Y, Yasukawa M, Furuuchi M, et al: An RNA-dependent RNA polymerase formed 66. Zhang Q, Davis JC, Lamborn IT, et al: Combined immunodeficiency associated with
by TERT and the RMRP RNA. Nature 461:230–235, 2009. DOCK8 mutations. N Engl J Med 361:2046–2055, 2009.
37. Smith A, Stanley P, Jones K, et al: The role of the integrin LFA-1 in T-lymphocyte migra- 67. Moshous D, Callebaut I, de Chasseval R, et al: Artemis, a novel DNA double-strand
tion. Immunol Rev 218:135–146, 2007. break repair/V(D)J recombination protein, is mutated in human severe combined
38. Saitta SC, Harris SE, Gaeth AP, et al: Aberrant interchromosomal exchanges are the immune deficiency. Cell 105:177–186, 2001.
predominant cause of the 22q11.2 deletion. Hum Mol Genet 13:417–428, 2004. 68. Enders A, Fisch P, Schwarz K, et al: A severe form of human combined immunodefi-
39. McLean-Tooke A, Spickett GP, Gennery AR: Immunodeficiency and autoimmunity in ciency due to mutations in DNA ligase IV. J Immunol 176:5060–5068, 2006.
22q11.2 deletion syndrome. Scand J Immunol 66:1–7, 2007. 69. Villa A, Sobacchi C, Notarangelo LD, et al: V(D)J recombination defects in lympho-
40. Nezelof C: Thymic pathology in primary and secondary immunodeficiencies. Histopa- cytes due to RAG mutations: Severe immunodeficiency with a spectrum of clinical pre-
thology 21:499–511, 1992. sentations. Blood 97:81–88, 2001.
41. Lima K, Abrahamsen TG, Foelling I, et al: Low thymic output in the 22q11.2 deletion 70. Noordzij JG, Verkaik NS, van der Burg M, et al: Radiosensitive SCID patients with
syndrome measured by CCR9+CD45RA+ T cell counts and T cell receptor rearrange- Artemis gene mutations show a complete B-cell differentiation arrest at the pre–B-cell
ment excision circles. Clin Exp Immunol 161:98–107, 2010. receptor checkpoint in bone marrow. Blood 101:1446–1452, 2003.
42. Sullivan KE, McDonald-McGinn D, Zackai EH: CD4(+) CD25(+) T-cell production 71. Buck D, Malivert L, de Chasseval R, et al: Cernunnos, a novel nonhomologous end-
in healthy humans and in patients with thymic hypoplasia. Clin Diagn Lab Immunol joining factor, is mutated in human immunodeficiency with microcephaly. Cell
9:1129–1131, 2002. 124:287–299, 2006.
43. de la Calle-Martin O, Hernandez M, Ordi J, et al: Familial CD8 deficiency due to a 72. Morice WG, Leibson PJ, Tefferi A: Natural killer cells and the syndrome of chronic
mutation in the CD8 alpha gene. J Clin Invest 108:117–123, 2001. natural killer cell lymphocytosis. Leuk Lymphoma 41:277–284, 2001.
44. Recio MJ, Moreno-Pelayo MA, Kilic SS, et al: Differential biological role of CD3 chains 73. Chee CE, Warrington KJ, Tefferi A: Chronic natural killer-cell lymphocytosis success-
revealed by human immunodeficiencies. J Immunol 178:2556–2564, 2007. fully treated with alemtuzumab. Blood 114:3500–3502, 2009.
45. Frank J, Pignata C, Panteleyev AA, et al: Exposing the human nude phenotype. Nature 74. Rabbani GR, Phyliky RL, Tefferi A: A long-term study of patients with chronic natural
398:473–474, 1999. killer cell lymphocytosis. Br J Haematol 106:960–966, 1999.
46. Roifman CM: Human IL-2 receptor alpha chain deficiency. Pediatr Res 48:6–11, 2000. 75. Kano Y, Shiohara T: The variable clinical picture of drug-induced hypersensitivity syn-
47. Kofoed EM, Hwa V, Little B, et al: Growth hormone insensitivity associated with a drome/drug rash with eosinophilia and systemic symptoms in relation to the eliciting
STAT5b mutation. N Engl J Med 349:1139–1147, 2003. drug. Immunol Allergy Clin North Am 29:481–501, 2009.
48. Hunter KB, Lucke T, Spranger J, et al: Schimke immunoosseous dysplasia: Defining 76. Teggatz JR, Parkin J, Peterson L: Transient atypical lymphocytosis in patients with
skeletal features. Eur J Pediatr 169:801–811, 2010. emergency medical conditions. Arch Pathol Lab Med 111:712–714, 1987.
49. Roberts JL, Lengi A, Brown SM, et al: Janus kinase 3 (JAK3) deficiency: Clinical, immu- 77. Troussard X, Mossafa H, Valensi F, et al: [Polyclonal lymphocytosis with binucleated
nologic, and molecular analyses of 10 patients and outcomes of stem cell transplanta- lymphocytes. Morphological, immunological, cytogenetic and molecular analysis in 15
tion. Blood 103:2009–2018, 2004. cases] [in French]. Presse Med 26:895–899, 1997.
50. Bosticardo M, Marangoni F, Aiuti A, et al: Recent advances in understanding the patho- 78. Juneja S, Januszewicz E, Wolf M, Cooper I: Post-splenectomy lymphocytosis. Clin Lab
physiology of Wiskott-Aldrich syndrome. Blood 113:6288–6295, 2009. Haematol 17:335–337, 1995.
51. Kim VH, Murguia L, Schechter T, et al: Emergency treatment for zeta chain-associated 79. Virella G: Immune complex diseases. Immunol Ser 50:395–414, 1990.
protein of 70 kDa (ZAP70) deficiency. J Allergy Clin Immunol 131:1233–1235, 2013. 80. Gao W, Pereira MA: Trypanosoma cruzi trans-sialidase potentiates T cell activation
52. Picard C, Dogniaux S, Chemin K, et al: Hypomorphic mutation of ZAP70 in human through antigen-presenting cells: Role of IL-6 and Bruton’s tyrosine kinase. Eur J Immu-
results in a late onset immunodeficiency and no autoimmunity. Eur J Immunol nol 31:1503–1512, 2001.
39:1966–1976, 2009. 81. Spach DH, Koehler JE: Bartonella-associated infections. Infect Dis Clin North Am
53. Jayadev S, Bird TD: Hereditary ataxias: Overview. Genet Med 15:673–683, 2013. 12:137–155, 1998.
54. Pai SY, Logan BR, Griffith LM, et al: Transplantation outcomes for severe combined 82. Im JS, Kang TJ, Lee SB, et al: Alteration of the relative levels of iNKT cell subsets is
immunodeficiency, 2000–2009. N Engl J Med 371:434–446, 2014. associated with chronic mycobacterial infections. Clin Immunol 127:214–224, 2008.
55. Cassani B, Mirolo M, Cattaneo F, et al: Altered intracellular and extracellular signaling 83. Wenzel J, Gerdsen R, Uerlich M, et al: Lymphocytopenia in lupus erythematosus: Close
leads to impaired T-cell functions in ADA-SCID patients. Blood 111:4209–4219, 2008. in vivo association to autoantibodies targeting nuclear antigens. Br J Dermatol 150:
56. Candotti F: Gene transfer into hematopoietic stem cells as treatment for primary 994–998, 2004.
immunodeficiency diseases. Int J Hematol 99:383–392, 2014. 84. Mandl T, Bredberg A, Jacobsson LT, et al: CD4+ T-lymphocytopenia—A frequent
57. Buckley RH: Immunodeficiency diseases. JAMA 268:2797–2806, 1992. finding in anti-SSA antibody seropositive patients with primary Sjögren’s syndrome. J
58. Tchilian EZ, Wallace DL, Wells RS, et al: A deletion in the gene encoding the CD45 Rheumatol 31:726–728, 2004.
antigen in a patient with SCID. J Immunol 166:1308–1313, 2001. 85. Gentil B, Cottin V, Girard P, Cordier JF: Ambivalence of CD4 lymphocytopenia in sar-
59. Buckley RH: Molecular defects in human severe combined immunodeficiency and coidosis. Sarcoidosis Vasc Diffuse Lung Dis 20:74–75, 2003.
approaches to immune reconstitution. Annu Rev Immunol 22:625–655, 2004.

Kaushansky_chapter 78_p1195-1198.indd 1198 9/18/15 9:59 AM